177Lu-AB-3PRGD2 in Patients With Integrin αVβ3 Positive Tumors

Summary

This is an open-label, non-controlled, non-randomized study to assess the safety and measure image-based absorbed dose of 177Lu-AB-3PRGD2 in patients with Integrin αVβ3 positive tumors who will undergo radioliagnd therapy using 177Lu-AB-3PRGD2.

Timeline

Start

2021-10-01

Primary completion

2024-10-30

Completion

2024-12-01

Drugs

Indications

No indication recorded.